Related references
Note: Only part of the references are listed.Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection
Evan J. Zasowski et al.
OPEN FORUM INFECTIOUS DISEASES (2022)
The Penicillin Allergy Delabeling Program: A Multicenter Whole-of-Hospital Health Services Intervention and Comparative Effectiveness Study
Kyra Y. L. Chua et al.
CLINICAL INFECTIOUS DISEASES (2021)
Vancomycin Advanced Therapeutic Drug Monitoring: Exercise in Futility or Virtuous Endeavor to Improve Drug Efficacy and Safety?
Thomas J. Dilworth et al.
CLINICAL INFECTIOUS DISEASES (2021)
Environmental conditions dictate differential evolution of vancomycin resistance in Staphylococcus aureus
Henrique Machado et al.
COMMUNICATIONS BIOLOGY (2021)
Comparative Effectiveness of Switching to Daptomycin Versus Remaining on Vancomycin Among Patients With Methicillin-resistant Staphylococcus aureus (MRSA) Bloodstream Infections
Marin L. Schweizer et al.
CLINICAL INFECTIOUS DISEASES (2021)
Validity of 2020 vancomycin consensus recommendations and further guidance for practical application
Michael J. Rybak et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2021)
Current Paradigms of Combination Therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients?
Warren Rose et al.
CLINICAL INFECTIOUS DISEASES (2021)
Recent Trends in Infective Endocarditis among Patients with and without Injection Drug Use: An Eight-Year Single Center Study
Javier Balda et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2021)
Impact of a vancomycin loading dose on the achievement of target vancomycin exposure in the first 24 h and on the accompanying risk of nephrotoxicity in critically ill patients
C. J. Hodiamont et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes
Emi Minejima et al.
CLINICAL INFECTIOUS DISEASES (2020)
The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE)
Thomas P. Lodise et al.
CLINICAL INFECTIOUS DISEASES (2020)
Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia A Randomized Clinical Trial
Steven Y. C. Tong et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Therapeutic monitoring of vancomycin for serious -methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists
Michael J. Rybak et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2020)
Cost comparison of AUC:MIC- versus trough-based vancomycin monitoring for MRSA bacteremia
Mario V. Beccari et al.
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION (2020)
Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study
Richard Kuehl et al.
LANCET INFECTIOUS DISEASES (2020)
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis
Aref Shariati et al.
SCIENTIFIC REPORTS (2020)
Vital Signs: Epidemiology and Recent Trends in Methicillin-Resistant and in Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections - United States
Athena P. Kourtis et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis
Alessandro Cassini et al.
LANCET INFECTIOUS DISEASES (2019)
Systematic Review and Meta-analysis of the Safety of Antistaphylococcal Penicillins Compared to Cefazolin
Khalid Eljaaly et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Invasive Methicillin-Resistant Staphylococcus aureus Infections Among Persons Who Inject Drugs — Six Sites, 2005–2016
Kelly A. Jackson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2018)
Busting the Myth of Static vs Cidal: A Systemic Literature Review
Noah Wald-Dickler et al.
CLINICAL INFECTIOUS DISEASES (2018)
Correcting a Fundamental Flaw in the Paradigm for Antimicrobial Susceptibility Testing
Selvi C. Ersoy et al.
EBIOMEDICINE (2017)
Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review
Reese A. Cosimi et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
The Nephrotoxicity of Vancomycin
E. J. Filippone et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
The Safety and Economic Impact of Cefazolin versus Nafcillin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections
Lauren K. Flynt et al.
INFECTIOUS DISEASES AND THERAPY (2017)
Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations
Sujata M. Bhavnani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
Kimberly C. Claeys et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications A Scientific Statement for Healthcare Professionals From the American Heart Association
Larry M. Baddour et al.
CIRCULATION (2015)
Avoiding the Perfect Storm: The Biologic and Clinical Case for Reevaluating the 7-Day Expectation for Methicillin-Resistant Staphylococcus aureus Bacteremia Before Switching Therapy
Ravina Kullar et al.
CLINICAL INFECTIOUS DISEASES (2014)
Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients
Chung-Chih Lai et al.
BMC INFECTIOUS DISEASES (2013)
Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia With Vancomycin Minimum Inhibitory Concentration >1 mg/L: A Matched Cohort Study
Kyle P. Murray et al.
CLINICAL INFECTIOUS DISEASES (2013)
Organic Anion Transporter 3 Interacts Selectively with Lipophilic β-Lactam Antibiotics
Aaron T. Wolman et al.
DRUG METABOLISM AND DISPOSITION (2013)
Elevated Serum Interleukin-10 at Time of Hospital Admission Is Predictive of Mortality in Patients With Staphylococcus aureus Bacteremia
Warren E. Rose et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Applying New Diagnostic Criteria for Acute Kidney Injury To Facilitate Early Identification of Nephrotoxicity in Vancomycin-Treated Patients
Emi Minejima et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children: Executive Summary
Catherine Liu et al.
CLINICAL INFECTIOUS DISEASES (2011)
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children
Catherine Liu et al.
CLINICAL INFECTIOUS DISEASES (2011)
High-Dose Daptomycin for Treatment of Complicated Gram-Positive Infections: A Large, Multicenter, Retrospective Study
Ravina Kullar et al.
PHARMACOTHERAPY (2011)
High-dose daptomycin in documented Staphylococcus aureus infections
Matteo Bassetti et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
Vance G. Fowler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Staphylococcus aureus endocarditis -: A consequence of medical progress
VG Fowler et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Share Paper
